All News
Filter News
Found 73,703 articles
-
BioLife Solutions to Acquire SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry
9/21/2020
BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has entered into a definitive agr
-
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
9/21/2020
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that it intends to offer and sell shares of its common stock and Series 1 convertible preferred stock in two concurrent but separate underwritten public offerings (together, the “Offerings”). The Offerings are subject to market and other conditions, and the
-
Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies
9/21/2020
Immune Regulation Limited (“Immune Regulation”), a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding round led by Boston based Morningside Ventures (“Morningside”), alongside existing shareholders including London based 24Haymarket.
-
Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
9/21/2020
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women wi
-
CDC Compromised by Bias and Conflicts of Interest, Writes Editor of the Journal of American Physicians and Surgeons
9/21/2020
The Centers for Disease Control and Prevention (CDC), which according to its website is "recognized as the nation's premiere health promotion, prevention and preparedness agency," is playing a leading role in response to the COVID-19 pandemic. In the fall issue of the Journal of American Physicians and Surgeons , editor-in-c
-
Visby Medical's Personal PCR Device Receives FDA Emergency Use Authorization For Moderate-Complexity Lab Environments
9/21/2020
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) on September 16, 2020, for Visby Medical's single-use Personal PCR (polymerase chain reaction) device, a rapid test for detection of COVID-19.
-
Reduce The Number Of Men With Delayed Prostate Cancer Diagnosis Due To COVID
9/21/2020
Prostate Conditions Education Council works to stop the delayed diagnosis of prostate cancer due to COVID-19 by offering free screenings
-
FDA Report: DiaCarta COVID-19 Tests Rank Top 3 Among FDA SARS-CoV-2 Reference Panel Tests
9/21/2020
According to the recent FDA SARS-CoV-2 Reference Panel Comparative Data released on September 15, among all the FDA EUA tests with returned results, DiaCarta’s QuantiVirus TM SARS-CoV-2 Test and QuantiVirus TM SARS-CoV-2 Multiplex Test both rank within the top 3 for product sensitivity. With limit of detection (LoD) at 600 NDU/ml, these tests are 300 to 900-folds better than the least sensitive tests listed (180,00
-
CHOP Researchers Find MIS-C Associated with Myocardial Injury
9/21/2020
--Long-term effects of MIS-C on cardiac function will need further study, as myocardial injury could have implications for future sports participation-- [21-September-2020] PHILADELPHIA , Sept. 21, 2020 /PRNewswire/ -- Using sensitive parameters to assess cardiac function, researchers at Children's Hospital of Philadelphia (CHOP) have found that cardiac involvemen
-
Tiziana Life Sciences plc: Publication of Research Note
9/21/2020
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1 About Tiziana Life Sciences Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology c
-
Misonix Enters Into Exclusive Supply and Distribution Agreement With Gunze Limited for TheraGenesis® Bilayer Wound MatrixExpands Misonix’s Wound Tissue Regeneration Franchise and Complements Nexus SonicOne® Strategy
9/21/2020
Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products that enhance clinical outcomes, announced today that it has entered into an exclusive supply and distribution agreement with Gunze Limited for TheraGenesis ® Bilayer Wound Matrix. TheraGenesis is a proprietary, FDA cleared, porcine tendon derived collagen wound matrix with a silicone film layer
-
Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
9/21/2020
Cabozantinib in combination with atezolizumab demonstrated promising preliminary efficacy and a favorable safety profile in cohorts of patients with clear cell and non-clear cell renal cell carcinoma – – Data presented during the European Society for Medical Oncology Virtual Congress 2020 – ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 1b clinical trial results for the combination o
-
New Study Offers Hope for Patients with Diabetes and Advanced Kidney Disease
9/21/2020
A new study released today in the National Kidney Foundation's American Journal of Kidney Diseases (AJKD) shows that the drug canagliflozin reduces the risk of adverse cardiovascular and kidney outcomes in people with type 2 diabetes
-
Amazfit Band 5 Launched with Blood Oxygen Saturation, 15-day Battery Life[1] at 44.9USD[2] on Sept. 21st, and Amazon Alexa Built-in[3] Coming Soon
9/21/2020
Amazfit Band 5, a smart wrist band, launched as the latest offering of Huami to the excellence of Amazfit wearable lineup.
-
Theratechnologies Announces Preliminary Third-Quarter Fiscal 2020 Financial Results
9/21/2020
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter ended August 31, 2020. For the third quarter of fiscal year 2020, the company expects consolidated net revenues to be between $13.8 million and $14.2 million compared to $16.1 million for the third quarter
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
9/21/2020
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer
-
Daré Bioscience Receives $0.9 million Under the Current Grant
9/21/2020
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received the final approximately $0.9 million in funding under the current grant from the Bill & Melinda Gates Foundation. The grant payment will support ongoing development activities for Daré’s investigational user-controlled, long-acting reversible contraceptive (UC-LARC), DARE-LARC1. Development of DARE-LARC1 has been supported by approximate
-
Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy
9/21/2020
Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs
-
Pathline Labs Doubles Testing Capacity for COVID-19, Adds Major Clients Throughout U.S.
9/21/2020
Pathline Labs, a leading provider of sub-specialized anatomic pathology, has expanded its COVID-19 testing capabilities across the country while maintaining a 24-36-hour turnaround time for processing.
-
Willow Biosciences announces successful production of pure cannabigerol
9/21/2020
Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has successfully developed a scalable process for producing cannabigerol (" CBG ") with greater than 99% purity and no detectable THC and demonstrated production at 500 litre scale.